Get started
Author

Alexis Ostinelli

Observed names: A. Ostinelli, C.A. Ostinelli, Cristian A. Ostinelli, Cristian Alexis Ostinelli, Ostinelli, Alexis
OpenAlex ID: A5029902791
The Emerging Role of Tertiary Lymphoid Structures in Breast Cancer: A Narrative Review
2024 · Dana Narvaez, Jorge Nadal, et al. · Cancers · 24
PDF
CDK4/6 inhibitors outcomes in patients with advanced breast cancer based on HER2-low expression.
2022 · Laura Sabina Lapuchesky, Marcos Bortz, et al. · Journal of Clinical Oncology · 14
HER2-Directed Therapy in Advanced Breast Cancer: Benefits and Risks
2023 · Pablo Mandó, Federico Waisberg, et al. · OncoTargets and Therapy · 9
PDF
Phenotypic and functional analysis in HER2+ targeted therapy of human NK cell subpopulation according to the expression of FcεRIγ and NKG2C in breast cancer patients
2023 · María B. Bordignon, Ayelén I. Pesce Viglietti, et al. · Cancer Immunology Immunotherapy · 3
PDF
Physician treatment decisions for hormone receptor-positive, HER2-negative early breast cancer in young patients: a Latin American survey
2025 · Dana Narvaez, Federico Waisberg, et al. · Therapeutic Advances in Medical Oncology · 1
In-Depth Analysis of the Peripheral Immune Profile of HER2+ Breast Cancer Patients on Neoadjuvant Treatment with Chemotherapy Plus Trastuzumab Plus Pertuzumab
2024 · Ayelén Ivana Pesce Viglietti, María Belén Bordignon, et al. · International Journal of Molecular Sciences · 1
PDF
Impact of peridiagnostic genetic counseling and germline testing on treatment decisions for patients with triple negative breast cancer undergoing pembrolizumab-chemotherapy neoadjuvant approach.
2024 · Luisina Ines Bruno, Guillermo Alberto, et al. · Journal of Clinical Oncology · 1
The role of modern parameters and their relationship with recurrence risk as assessed by Oncotype DX: real-world evidence
2024 · Dana Narvaez, Jorge Nadal, et al. · ecancermedicalscience · 1
PDF
46P PIK3CA mutation impact in prognosis of advanced HR+/HER2-negative breast cancer patients: Collaborative multicentric Argentinean real-world study (YOGA-B-01)
2023 · P. Mando, F.D. Waisberg, et al. · ESMO Open · 1
PDF
Efficacy and toxicity of endocrine therapy + cyclin-dependent kinases 4/6 inhibitors (iCDK4/6) in metastatic breast cancer patients according to gBRCA status
2018 · L.I. Bruno, M.V. Costanzo, et al. · Annals of Oncology · 1
Abstract PS3-11-02: Exploring heterogeneity of HER2 immunohistochemistry staining in patients undergoing neoadjuvant breast cancer treatment in two cancer centers of South America
2026 · M. Ancao, M. Costanzo, et al. · Clinical Cancer Research
Abstract P4-01-11: Patient-reported outcomes assessment using mobile applications in the HR+/Her2- breast cancer adjuvant setting
2025 · Federico Waisberg, Alexis Ostinelli, et al. · Clinical Cancer Research
Abstract P4-11-15: Variability in physician treatment decisions for HR+ / HER 2 negative Early Breast Cancer in young patients: a Latin-American survey
2025 · Dana P. Narvaez, Federico Waisberg, et al. · Clinical Cancer Research
MRI concentric partial response pattern as a predictor of pathological complete response in early triple-negative breast cancer treated with Keynote-522 neoadjuvant therapy.
2025 · Dana Narvaez, Federico Waisberg, et al. · Journal of Clinical Oncology
Evaluación de toxicidad relacionada al tiempo en una cohorte de pacientes con cáncer de mama avanzado RH+/HER2- en tratamiento con ribociclib
2024 · Dana Narvaez, Danilo Aguirre, et al. · Oncología Clínica
PDF
Fractura vertebral dorsal secundaria a Enfermedad De Paget
2024 · Ramírez Stieben, Luis Agustín, Caballini, Pablo, et al. · Actualizaciones en osteología
PDF
Abstract PO4-16-07: Cyclin-dependent kinase inhibitor plus endocrine therapy in HR+/HER2- invasive breast cancer with bone marrow and pancytopenia: a new standard of care? Collaborative multicentric Argentinean real-world study (SUMA-02)
2024 · Alexis Ostinelli, Pablo Mandó, et al. · Cancer Research
Abstract PO5-02-03: Does the recommendation of adjuvant CDK4/6 inhibitors implicate more ovarian suppression in premenopausal patients? A real-world study of a public and a private Argentinean institution
2024 · Vanesa Lopez, Dana Narvaez, et al. · Cancer Research
Análisis del polimorfismo FcƴRIII en pacientes con cáncer de mama HER2+ en tratamiento neoadyuvante con Quimioterapia más trastuzumab y pertuzumab
2023 · Ayelen Ivana Pesce Viglietti, María Belén Bordignon, et al. · Oncología Clínica
PDF
Appraising the quality of meta-analysis for breast cancer treatment in the adjuvant setting: A systematic review
2021 · Pablo Mandó, Ian Hirsch, et al. · Cancer Treatment and Research Communications
PDF
Oropharyngeal Carcinoma related to human papillomavirus (HPV). A Latin American Experience.
2020 · A.H. Falco, M. Angel, et al. · International Journal of Radiation Oncology*Biology*Physics
Abstract P2-08-05: Early breast cancer in oldest population: Screening, tumor characteristics and treatment choices in octogenarian women
2020 · Sergio G Rivero, Alexis Ostinelli, et al. · Cancer Research
Assessing the Needs and the Quality of Life of Women With Advanced Breast Cancer
2018 · M.G. Berta, M. Chacón, et al. · Journal of Global Oncology
Los linfocitos estromales intratumorales (tils) como factor pronóstico en tumores primarios de mama Triple Negativos
2018 · Mora Amat, Pablo Mandó, et al.
Lesiones Cutáneas Asociadas a Factores Estimulantes De Colonias En Una Paciente Con Cáncer De Pulmón
2017 · Alexis Ostinelli, Walter Astorino, et al. · REVISTA ARGENTINA DE MEDICINA
PDF
Works count: 26
Citation count: 56
H-index: 3
I10-index: 2
Year
Topic
Type